PrihodDobitKGVKUVEBITDividendaDioniceTržišna kapitalizacijaDugovanjeObvezeTemeljni kapitalAAQSzaposleniciROEROAROCE
Titan Pharmaceuticals Dionica

Titan Pharmaceuticals AAQS 2024

Titan Pharmaceuticals AAQS

2

Ticker

TTNP

ISIN

US8883146065

WKN

A2QJPT

Titan Pharmaceuticals ima trenutni AAQS od 2. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice Titan Pharmaceuticals s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.

Titan Pharmaceuticals Aktienanalyse

Što radi Titan Pharmaceuticals?

Titan Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and marketing of innovative drugs for the treatment of central nervous system disorders. The company was founded in 1992 and is headquartered in South San Francisco, California. The business model of Titan Pharmaceuticals Inc is to develop new technologies and therapies that help patients achieve a better quality of life. The company collaborates closely with research institutions and other industry companies to incorporate the latest scientific findings into its products. Over the years, Titan Pharmaceuticals Inc has developed numerous products focusing on various areas of the medical field. The emphasis is on researching better treatment options for conditions such as opioid dependence, pain management, and Parkinson's disease. One example of Titan Pharmaceuticals Inc's portfolio is the opioid agonist Probuphine. This drug is implanted in the arm in the form of an implant and continuously releases an active ingredient over a period of six months to help treat opioid dependence. Probuphine has been approved by the US Food and Drug Administration (FDA) and is the first medication of its kind. Another example of Titan Pharmaceuticals Inc's portfolio is the Parkinson's medication Forsight. This drug aims to alleviate the symptoms of Parkinson's by supporting the release of dopamine in the brain. Forsight was granted clinical trial approval by the US Food and Drug Administration in 2020. In recent years, Titan Pharmaceuticals Inc has also established close collaborations with other companies in the medical field. For example, in 2018, Titan Pharmaceuticals Inc signed a contract with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A for the marketing of Probuphine in the European market. Under this agreement, L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A acquired exclusive distribution rights for Probuphine in Europe and is responsible for its marketing in Europe. Overall, Titan Pharmaceuticals Inc has an impressive track record in medical research and development. The company has brought several innovative products to the market and continues to work on developing new medications that improve patients' quality of life. With a dedicated research and development department and a strong market position, Titan Pharmaceuticals Inc is well positioned to succeed in the pharmaceutical industry in the future. Titan Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Česta pitanja o Titan Pharmaceuticals dionici

Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.

Andere Kennzahlen von Titan Pharmaceuticals

Naša analiza dionica Titan Pharmaceuticals Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Titan Pharmaceuticals Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: